The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature

Psychotherapy and Psychosomatics

Volumn 85, Issue 5, 2016, Pages 270-288

  Carvalho, André F ^a   Sharma, Manu S ^c   Brunoni, André R ^b   Vieta, Eduard ^e   Fava, Giovanni A ^d,f  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Adverse events; Antidepressant drugs; Depression; Iatrogenic comorbidity; Safety; Selective serotonin reuptake inhibitors; Serotonin noradrenaline reuptake inhibitors; Side effects; Tolerability; Tricyclic antidepressants

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; MILNACIPRAN; MIRTAZAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VILAZODONE; VORTIOXETINE; ANTIDEPRESSANT AGENT;

ARTICLE; BLEEDING; BREAST FEEDING; CATARACT; COGNITIVE DEFECT; DIARRHEA; DRUG CHOICE; DRUG INDUCED CANCER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FRACTURE; GLAUCOMA; HEART ARRHYTHMIA; HIGH RISK PREGNANCY; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; HYPONATREMIA; IATROGENIC DISEASE; LIVER TOXICITY; MAJOR DEPRESSION; META ANALYSIS (TOPIC); METABOLIC DISORDER; MOOD DISORDER; NAUSEA; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; PARADOXICAL DRUG REACTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SEIZURE; SEIZURE THRESHOLD; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; STOMACH HEMORRHAGE; SUICIDAL BEHAVIOR; SWEATING; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); URINE INCONTINENCE; URINE RETENTION; WEIGHT GAIN; WITHDRAWAL SYNDROME; DEPRESSIVE DISORDER, MAJOR; RISK FACTOR;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; RISK FACTORS;

EID: 84981510256     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000447034     Document Type: Article

References (249)

1. Kessler RC: The costs of depression. Psychiatr Clin North Am 2012; 35: 1-14.
2. Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.
3. Pratt LA, Brody DJ, Gu Q: Antidepressant use in persons aged 12 and over: United States, 2005-2008. NCHS Data Brief 2011; 76: 1-8.
4. Castro-Rodríuez JI, Olariu E, Garnier- Lacueva C, Mart í-López LM, Pérez-Solà V, Alonso J, Forero CG; INSAyD Investigators: Diagnostic accuracy and adequacy of treatment of depressive and anxiety disorders: a comparison of primary care and specialized care patients. J Affect Disord 2015; 172: 462-471.
5. Duhoux A, Fournier L, Gauvin L, Roberge P: What is the association between quality of treatment for depression and patient outcomes? A cohort study of adults consulting in primary care. J Affect Disord 2013; 151: 265-274.
6. Yau WY, Chan MC, Wing YK, Lam HB, Lin W, Lam SP, Lee CP: Noncontinuous use of antidepressant in adults with major depressive disorders - a retrospective cohort study. Brain Behav 2014; 4: 390-397.
7. Hung CI: Factors predicting adherence to antidepressant treatment. Curr Opin Psychiatry 2014; 27: 344-349.
8. Fortney JC, Pyne JM, Edlund MJ, Stecker T, Mittal D, Robinson DE, Henderson KL: Reasons for antidepressant nonadherence among veterans treated in primary care clinics. J Clin Psychiatry 2011; 72: 827-834.
9. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW: Discontinuing or switching selective serotoninreuptake inhibitors. Ann Pharmacother 2002; 36: 578-584.
10. Anderson IM: Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19-36.
11. Machado-Vieira R, Henter ID, Zarate CA: New targets for rapid antidepressant action. Prog Neurobiol 2015, Epub ahead of print.
12. Rosenblat JD, McIntyre RS, Alves GS, Fountoulakis KN, Carvalho AF: Beyond monoamines- novel targets for treatment-resistant depression: a comprehensive review. Curr Neuropharmacol 2015; 13: 636-655.
13. Hatcher S, Arroll B: Newer antidepressants for the treatment of depression in adults. BMJ 2012; 344:d8300-d8300.
14. Elmaadawi A, Singh N, Reddy J: Prescriber's guide to using 3 new antidepressants. Curr Psychiatry 2016; 14: 32-36.
15. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-758.
16. Khoo AL, Zhou HJ, Teng M, Lin L, Zhao YJ, Soh LB, Mok YM, Lim BP, Gwee KP: Network meta-analysis and cost-effectiveness analysis of new generation antidepressants. CNS Drugs 2015; 29: 695-712.
17. Baghai TC, Blier P, Baldwin DS, Bauer M, Goodwin GM, Fountoulakis KN, Kasper S, Leonard BE, Malt UF, Stein D, Versiani M, Möller HJ; Section of Pharmacopsychiatry, World Psychiatric Association: General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 2011; 261(suppl): 207-245.
18. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN: Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008; 149: 734-750.
19. Fountoulakis KN, McIntyre RS, Carvalho AF: From randomized controlled trials of antidepressant drugs to the meta-analytic synthesis of evidence: methodological aspects lead to discrepant findings. Curr Neuropharmacol 2015; 13: 605-615.
20. von Wolff A, Hölzel LP, Westphal A, Härter M, Kriston L: Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and metaanalysis. J Affect Disord 2013; 144: 7-15.
21. Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles M, Geddes J, Hardy R, Lewis G, Mason J: Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev 2000; 4:CD002791.
22. Thase ME, Denko T: Pharmacotherapy of mood disorders. Annu Rev Clin Psychol 2008; 4: 53-91.
23. Peretti S, Judge R, Hindmarch I: Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 17-25.
24. Moret C, Isaac M, Briley M: Problems associated with long-term treatment with selective serotonin reuptake inhibitors. J Psychopharmacol 2009; 23: 967-974.
25. Whiskey E, Taylor D: A review of the adverse effects and safety of noradrenergic antidepressants. J Psychopharmacol 2013; 27: 732-739.
26. Gershon MD: 5-hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes 2013; 20: 14-21.
27. Janssen P, Vos R, Tack J: The influence of citalopram on interdigestive gastrointestinal motility in man. Aliment Pharmacol Ther 2010; 32: 289-295.
28. Browning KN: Role of central vagal 5-HT3 receptors in gastrointestinal physiology and pathophysiology. Front Neurosci 2015; 9: 413.
29. Goldstein BJ, Goodnick PJ: Selective serotonin reuptake inhibitors in the treatment of affective disorders - III: tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998; 12:S55-S87.
30. Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, Kozel D, Hauser J, Souery D, Placentino A, Strohmaier J, Perroud N, Zobel A, Rajewska-Rager A, Dernovsek MZ, Larsen ER, Kalember P, Giovannini C, Barreto M, McGuffin P, Aitchison KJ: Adverse reactions to antidepressants. Br J Psychiatry 2009; 195: 202-210.
31. Wang YP, Chen YT, Tsai CF, Li SY, Luo JC, Wang SJ, Tang CH, Liu CJ, Lin HC, Lee FY, Chang FY, Lu CL: Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry 2014; 171: 54-61.
32. Mackay FJ, Dunn NR, Wilton LV, Pearce GL, Freemantle SN, Mann RD: A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf 1997; 6: 235-246.
33. Mackay FR, Dunn NR, Martin RM, Pearce GL, Freemantle SN, Mann RD: Newer antidepressants: a comparison of tolerability in general practice. Br J Gen Pract 1999; 49: 892-896.
34. Spigset O: Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999; 20: 277-287.
35. Gartlehner G, Hansen RA, Reichenpfader U, Kaminski A, Kien C, Strobelberger M, van Noord M, Thieda P, Thaler K, Gaynes B: Drug Class Review: Second-Generation Antidepressants: Final Update 5 Report. Drug Class Reviews. Portland, Oregon Health and Science University, 2011.
36. DeVane CL: Immediate-release versus controlled- release formulations: pharmacokinetics of newer antidepressants in relation to nausea. J Clin Psychiatry 2003; 64(suppl 1):14-19.
37. Nussbaumer B, Morgan LC, Reichenpfader U, Greenblatt A, Hansen RA, van Noord M, Lux L, Gaynes BN, Gartlehner G: Comparative efficacy and risk of harms of immediateversus extended-release second-generation antidepressants: a systematic review with network meta-analysis. CNS Drugs 2014; 28: 699-712.
38. Asnis GM, Henderson MA: Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr Dis Treat 2015; 11: 125-135.
39. Meeker AS, Herink MC, Haxby DG, Hartung DM: The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Syst Rev 2015; 4: 21.
40. Yu SY, Zhang XF, Wu L, Wan DJ, Liu RZ, Dong Z, Chen M: Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder. Neuropsychiatr Dis Treat 2015; 11: 1957-1965.
41. Voican CS, Corruble E, Naveau S, Perlemuter G: Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 2014; 171: 404-415.
42. Chen M, Borlak J, Tong W: High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013; 58: 388-396.
43. Dara L, Liu Z-X, Kaplowitz N: Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int 2016; 36: 158-165.
44. Hussaini SH, Farrington EA: Idiosyncratic drug-induced liver injury: an update on the 2007 overview. Expert Opin Drug Saf 2014; 13: 67-81.
45. Choi S: Nefazodone (Serzone) withdrawn because of hepatotoxicity. CMAJ 2003; 169: 1187.
46. Freiesleben SD, Furczyk K: A systematic review of agomelatine-induced liver injury. J Mol Psychiatry 2015; 3: 4.
47. Mitkov MV, Trowbridge RM, Lockshin BN, Caplan JP: Dermatologic side effects of psychotropic medications. Psychosomatics 2014; 55: 1-20.
48. Bliss SA, Warnock JK: Psychiatric medications: adverse cutaneous drug reactions. Clin Dermatol 2013; 31: 101-109.
49. Hedenmalm K, Sundstrom A, Spigset O: Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs). Pharmacoepidemiol Drug Saf 2006; 15: 719-725.
50. Fava M: Weight gain and antidepressants. J Clin Psychiatry 2000; 61(suppl 1):37-41.
51. Serretti A, Mandelli L: Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71: 1259-1272.
52. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmächer T: Epidemiology, implications and mechanisms underlying druginduced weight gain in psychiatric patients. J Psychiatr Res 2003; 37: 193-220.
53. Lee SH, Paz-Filho G, Mastronardi C, Licinio J, Wong ML: Is increased antidepressant exposure a contributory factor to the obesity pandemic? Transl Psychiatry 2016; 6:e759.
54. Patten SB, Williams JV, Lavorato DH, Brown L, McLaren L, Eliasziw M: Major depression, antidepressant medication and the risk of obesity. Psychother Psychosom 2009; 78: 182-186.
55. Fava GA, Offidani E: The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1593-1602.
56. Sussman N, Ginsberg DL: Weight effects of nefazodone, bupropion, mirtazapine, and venlafaxine: a review of available evidence. Primary Psychiatry 2000; 7: 33-48.
57. Gadde KM, Parker CB, Maner LG, Wagner HR, Logue EJ, Drezner MK, Krishnan KR: Bupropion for weight loss: An investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001; 9: 544-551.
58. Silverstone PH, Ravindran A: Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 study group. J Clin Psychiatry 1999; 60: 22-28.
59. Citrome L: Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 2016; 196: 225-233.
60. Citrome L: Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2012; 66: 356-368.
61. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH: The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Expert Opin Drug Saf 2006; 5: 523-537.
62. Correll CU, Detraux J, De Lepeleire J, De Hert M: Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015; 14: 119-136.
63. Deuschle M: Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults. Curr Opin Psychiatry 2013; 26: 60-65.
64. Andersohn F, Schade R, Suissa S, Garbe E: Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166: 591-598.
65. Kivimaki M, Hamer M, Batty GD, Geddes JR, Tabak AG, Pentti J, Virtanen M, Vahtera J: Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care 2010; 33: 2611-2616.
66. Da Silva MA, Dugravot A, Balkau B, Roussel R, Fumeron F, Elbaz A, Canonico M, Singh- Manoux A, Nabi H: Antidepressant medication use and trajectories of fasting plasma glucose, glycated haemoglobin, β-cell function and insulin sensitivity: a 9-year longitudinal study of the D.E.S.I.R. Cohort. Int J Epidemiol 2015; 44: 1927-1940.
67. Bhattacharya R, Ajmera M, Bhattacharjee S, Sambamoorthi U: Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults. Diabetes Res Clin Pract 2014; 105: 251-260.
68. Bhattacharjee S, Bhattacharya R, Kelley GA, Sambamoorthi U: Antidepressant use and new-onset diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev 2013; 29: 273-284.
69. Kivimaki M, Batty GD, Jokela M, Ebmeier KP, Vahtera J, Virtanen M, Brunner EJ, Tabak AG, Witte DR, Kumari M, Singh-Manoux A, Hamer M: Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association? Biol Psychiatry 2011; 70: 978-984.
70. Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V: Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects: is there any? Curr Med Chem 1999; 6: 469-480.
71. Sarlon J, Habich O, Schneider B: Elevated rest heart rate in psychiatric patients and different effects of psychotropic medication. Pharmacopsychiatry 2016; 49: 18-22.
72. Thase ME, Larsen KG, Reines E, Kennedy SH: The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol 2013; 23: 1391-1400.
73. Kemp AH, Brunoni AR, Santos IS, Nunes MA, Dantas EM, Carvalho de Figueiredo R, Pereira AC, Ribeiro ALP, Mill JG, Andreão RV, Thayer JF, Benseñor IM, Lotufo PA: Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: an ELSA-Brasil cohort baseline study. Am J Psychiatry 2014; 171: 1328-1334.
74. Goldstein DJ: Duloxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2007; 3: 193-209.
75. O'Regan C, Kenny RA, Cronin H, Finucane C, Kearney PM: Antidepressants strongly influence the relationship between depression and heart rate variability: findings from the Irish longitudinal study on ageing (TILDA). Psychol Med 2015; 45: 623-636.
76. Taylor CB: Depression, heart rate related variables and cardiovascular disease. Int J Psychophysiol 2010; 78: 80-88.
77. Schatzberg AF, Blier P, Culpepper L, Jain R, Papakostas GI, Thase ME: An overview of vortioxetine. J Clin Psychiatry 2014; 75: 1411-1418.
78. Funk KA, Bostwick JR: A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother 2013; 47: 1330-1341.
79. Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC: QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 2013; 54: 1-13.
80. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, Huffman JC: Meta- analysis of selective serotonin reuptake inhibitor- associated QTc prolongation. J Clin Psychiatry 2014; 75:e441-e449.
81. Feighner JP: Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995; 56: 574-579.
82. Thase ME, Tran PV, Wiltse C, Pangallo BA, Mallinckrodt C, Detke MJ: Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005; 25: 132-140.
83. Pollock BG: Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry 1999; 60(suppl 2):4-8.
84. Rodriguez de la Torre B, Dreher J, Malevany I, Bagli M, Kolbinger M, Omran H, Lüderitz B, Rao ML: Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001; 23: 435-440.
85. Darowski A, Chambers SA, Chambers DJ: Antidepressants and falls in the elderly. Drugs Aging 2009; 26: 381-394.
86. Joo JH, Lenze EJ, Mulsant BH, Begley AE, Weber EM, Stack JA, Mazumdar S, Reynolds CF, Pollock BG: Risk factors for falls during treatment of late-life depression. J Clin Psychiatry 2002; 63: 936-941.
87. Cherin P, Colvez A, Deville de Periere G, Sereni D: Risk of syncope in the elderly and consumption of drugs: a case-control study. J Clin Epidemiol 1997; 50: 313-320.
88. Johnson EM, Whyte E, Mulsant BH, Pollock BG, Weber E, Begley AE, Reynolds CF: Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 2006; 14: 796-802.
89. Khawaja IS, Feinstein RE: Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants. Heart Dis 2003; 5: 153-160.
90. Verhamme KMC, Sturkenboom MC, Stricker BHC, Bosch R: Drug-induced urinary retention: Incidence, management and prevention. Drug Saf 2008; 31: 373-388.
91. Thor KB: Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Urology 2003; 62: 3-9.
92. Votolato NA, Stern S, Caputo RM: Serotonergic antidepressants and urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000; 11: 386-388.
93. Tsakiris P, Oelke M, Michel MC: Drug-induced urinary incontinence. Drugs Aging 2008; 25: 541-549.
94. Williams K, Reynolds MF: Sexual dysfunction in major depression. CNS Spectr 2006; 11: 19-23.
95. Clayton AH, Croft HA, Handiwala L: Antidepressants and sexual dysfunction: mechanisms and clinical implications. Postgrad Med 2014; 126: 91-99.
96. Serretti A, Chiesa A: Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29: 259-266.
97. Rizvi SJ, Yeung NW, Kennedy SH: Instruments to measure sexual dysfunction in community and psychiatric populations. J Psychosom Res 2011; 70: 99-109.
98. Kikuchi T, Uchida H, Suzuki T, Watanabe K, Kashima H: Patients' attitudes toward side effects of antidepressants: an internet survey. Eur Arch Psychiatry Clin Neurosci 2011; 261: 103-109.
99. Balon R, Segraves RT: Survey of treatment practices for sexual dysfunction(s) associated with anti-depressants. J Sex Marital Ther 2008; 34: 353-365.
100. Bella AJ, Shamloul R: Psychotropics and sexual dysfunction. Cent Eur J Urol 2013; 66: 466-471.
101. Reichenpfader U, Gartlehner G, Morgan LC, Greenblatt A, Nussbaumer B, Hansen RA, van Noord M, Lux L, Gaynes BN: Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf 2014; 37: 19-31.
102. Schweitzer I, Maguire K, Ng C: Sexual sideeffects of contemporary antidepressants: review. Aust NZ J Psychiatry 2009; 43: 795-808.
103. Gartlehner GH, Hansen RA, Reichenpfader UK, Kaminski A, Kien C, Strobelberger MN, van Noord M, Thieda P, Thaler K, Gaynes B: Drug Class Review: Second-Generation Antidepressants: Final Update 5 Report. Drug Class Reviews. Portland, Oregon Health and Science University, 2011.
104. Angst J: Sexual problems in healthy and depressed persons. Int Clin Psychopharmacol 1998; 13(suppl 6):S1-S4.
105. Montejo AL, Montejo L, Navarro-Cremades F: Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry 2015; 28: 418-423.
106. Clayton AH, El Haddad S, Iluonakhamhe J-P, Ponce Martinez C, Schuck AE: Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Expert Opin Drug Saf 2014; 13: 1361-1374.
107. Montgomery SA, Baldwin DS, Riley A: Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J Affect Disord 2002; 69: 119-140.
108. Segraves RT, Balon R: Antidepressant-induced sexual dysfunction in men. Pharmacol Biochem Behav 2014; 121: 132-137.
109. Pereira VM, Arias-Carrión O, Machado S, Nardi AE, Silva AC: Bupropion in the depression- related sexual dysfunction: a systematic review. CNS Neurol Disord Drug Targets 2014; 13: 1079-1088.
110. Csoka AB, Shipko S: Persistent sexual side effects after SSRI discontinuation. Psychother Psychosom 2006; 75: 187-188.
111. de Picker L, van Den Eede F, Dumont G, Moorkens G, Sabbe BGC: Antidepressants and the risk of hyponatremia: a class-byclass review of literature. Psychosomatics 2014; 55: 536-547.
112. Degner D, Grohmann R, Kropp S, Rüther E, Bender S, Engel RR, Schmidt LG: Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004; 37(suppl 1):S39-S45.
113. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J: Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011; 343:d4551.
114. Letmaier M, Painold A, Holl AK, Vergin H, Engel R, Konstantinidis A, Kasper S, Grohmann R: Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. Int J Neuropsychopharmacol 2012; 15: 739-748.
115. Jacob S: Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 2006; 40: 1618-1622.
116. Eom CS, Lee HK, Ye S, Park SM, Cho KH: Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res 2012; 27: 1186-1195.
117. Stubbs B, Brefka S, Dallmeier D, Stubbs J, Vancampfort D, Denkinger MD: Depression and reduced bone mineral density at the hip and lumbar spine: a comparative metaanalysis of studies in adults 60 years and older. Psychosom Med 2016; 78: 492-500.
118. Rosenblat JD, Gregory JM, Carvalho AF, McIntyre RS: Depression and disturbed bone metabolism: a narrative review of the epidemiological findings and postulated mechanisms. Curr Mol Med 2016; 16: 165-178.
119. Cizza G, Primma S, Csako G: Depression as a risk factor for osteoporosis. Trends Endocrinol Metab 2009; 20: 367-373.
120. Wu Q, Bencaz AF, Hentz JG, Crowell MD: Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int 2012; 23: 365-375.
121. Vestergaard P, Rejnmark L, Mosekilde L: Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int 2008; 82: 92-101.
122. Andrade C, Sandarsh S, Chethan KB, Nagesh KS: Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71: 1565-1575.
123. Pai VB, Kelly MW: Bruising associated with the use of fluoxetine. Ann Pharmacother 1996; 30: 786-788.
124. de Abajo FJ: Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging 2011; 28: 345-367.
125. Halperin D, Reber G: Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007; 9: 47-59.
126. Morriss R: Antidepressants are associated with hospital admitted intracranial bleeds in people taking other medication associated with bleeding. Evid Based Ment Health 2016; 19: 24.
127. Jiang HY, Chen HZ, Hu XJ, Yu ZH, Yang W, Deng M, Zhang YH, Ruan B: Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13: 42-50.e43.
128. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI: Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 811-819.
129. Perahia DG, Bangs ME, Zhang Q, Cheng Y, Ahl J, Frakes EP, Adams MJ, Martinez JM: The risk of bleeding with duloxetine treatment in patients who use nonsteroidal antiinflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports. Drug Healthc Patient Saf 2013; 5: 211-219.
130. de Abajo FJ, Garcí-Rodríguez LA: Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65: 795-803.
131. Cheng YL, Hu HY, Lin XH, Luo JC, Peng YL, Hou MC, Lin HC, Lee FY: Use of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding: a nationwide population- based cohort study in Taiwan. Medicine (Baltimore) 2015; 94:e2022.
132. Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J: Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009; 104: 1475-1482.
133. Paton C, Ferrier IN: SSRIS and gastrointestinal bleeding. BMJ 2005; 331: 529-530.
134. Haddad PM, Dursun SM: Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008; 23(suppl 1):15-26.
135. Hawthorne JM, Caley CF: Extrapyramidal reactions associated with serotonergic antidepressants. Ann Pharmacother 2015; 49: 1136-1152.
136. Leo RJ: Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57: 449-454.
137. Schillevoort I, van Puijenbroek EP, de Boer A, Roos RAC, Jansen PAF, Leufkens HGM: Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol 2002; 17: 75-79.
138. Gill HS, DeVane CL, Risch SC: Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997; 17: 377-389.
139. Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC: Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979; 45: 165-175.
140. Madhusoodanan S, Alexeenko L, Sanders R, Brenner R: Extrapyramidal symptoms associated with antidepressants - a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 2010; 22: 148-156.
141. Hedenmalm K, Güzey C, Dahl M-L, Yue Q-Y, Spigset O: Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006; 26: 192-197.
142. Konstantakopoulos G, Kouzoupis AV, Papageorgiou SG, Oulis P: Putative neuroleptic malignant syndrome associated with sertraline withdrawal. J Clin Psychopharmacol 2009; 29: 300-301.
143. Boyer EW, Shannon M: The serotonin syndrome. N Engl J Med 2005; 352: 1112-1120.
144. Iqbal MM, Basil MJ, Kaplan J, Iqbal MT: Overview of serotonin syndrome. Ann Clin Psychiatry 2012; 24: 310-318.
145. Isbister GK, Bowe SJ, Dawson A, Whyte IM: Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004; 42: 277-285.
146. Brvar M, Stajer D, Kozelj G, Osredkar J, Mozina M, Bunc M: Urinary serotonin level is associated with serotonin syndrome after moclobemide, sertraline, and citalopram overdose. Clin Toxicol (Phila) 2007; 45: 458-460.
147. Bortolato B, Miskowiak KW, Kohler CA, Maes M, Fernandes BS, Berk M, Carvalho AF: Cognitive remission: a novel objective for the treatment of major depression? BMC Med 2016; 14: 9.
148. Rosenblat JD, Kakar R, McIntyre RS: The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol 2015; 19:pyv082.
149. Bortolato B, Carvalho AF, McIntyre RS: Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review. CNS Neurol Disord Drug Targets 2014; 13: 1804-1818.
150. Wroolie TE, Williams KE, Keller J, Zappert LN, Shelton SD, Kenna HA, Reynolds MF, Rasgon NL: Mood and neuropsychological changes in women with midlife depression treated with escitalopram. J Clin Psychopharmacol 2006; 26: 361-366.
151. Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, Papakostas GI: A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 2006; 67: 1754-1759.
152. Anderson HD, Pace WD, Libby AM, West DR, Valuck RJ: Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study. Clin Ther 2012; 34: 113-123.
153. Shin D, Oh YH, Eom C-S, Park SM: Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and metaanalysis. J Neurol 2014; 261: 686-695.
154. Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J: Antidepressant use and risk of cardiovascular outcomes in people aged 20-64: cohort study using primary care database. BMJ 2016; 352:i1350.
155. Trindade E, Menon D, Topfer LA, Coloma C: Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998; 159: 1245-1252.
156. Marcy TR, Britton ML: Antidepressant-induced sweating. Ann Pharmacother 2005; 39: 748-752.
157. Cheshire WP, Fealey RD: Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management. Drug Saf 2008; 31: 109-126.
158. Ashton AK, Weinstein WL: Cyproheptadine for drug-induced sweating. Am J Psychiatry 2002; 159: 874-875.
159. Lauer CJ, Schreiber W, Holsboer F, Krieg JC: In quest of identifying vulnerability markers for psychiatric disorders by all-night polysomnography. Arch Gen Psychiatry 1995; 52: 145-153.
160. Arfken CL, Joseph A, Sandhu GR, Roehrs T, Douglass AB, Boutros NN: The status of sleep abnormalities as a diagnostic test for major depressive disorder. J Affect Disord 2014; 156: 36-45.
161. Wilson S, Argyropoulos S: Antidepressants and sleep: a qualitative review of the literature. Drugs 2005; 65: 927-947.
162. Tribl GG, Wetter TC, Schredl M: Dreaming under antidepressants: a systematic review on evidence in depressive patients and healthy volunteers. Sleep Med Rev 2013; 17: 133-142.
163. Rottach KG, Schaner BM, Kirch MH, Zivotofsky AZ, Teufel LM, Gallwitz T, Messer T: Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2008; 43: 70-75.
164. Salín-Pascual RJ, Galicia-Polo L, Drucker- Colín R: Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997; 58: 348-350.
165. Bayard M, Bailey B, Acharya D, Ambreen F, Duggal S, Kaur T, Rahman ZU, Roller K, Tudiver F: Bupropion and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 2011; 24: 422-428.
166. Price J, Cole V, Goodwin GM: Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry 2009; 195: 211-217.
167. Szmulewicz A, Samame C, Caravotta P, Martino DJ, Igoa A, Hidalgo-Mazzei D, Colom F, Strejilevich SA: Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications. Int J Bipolar Disord 2016; 4: 6.
168. Levy R, Dubois B: Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 2006; 16: 916-928.
169. Tondo L, Vazquez G, Baldessarini RJ: Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010; 121: 404-414.
170. Sani G, Napoletano F, Vohringer PA, Sullivan M, Simonetti A, Koukopoulos A, Danese E, Girardi P, Ghaemi N: Mixed depression: clinical features and predictors of its onset associated with antidepressant use. Psychother Psychosom 2014; 83: 213-221.
171. Offidani E, Fava GA, Tomba E, Baldessarini RJ: Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. Psychother Psychosom 2013; 82: 132-141.
172. Harada T, Sakamoto K, Ishigooka J: Incidence and predictors of activation syndrome induced by antidepressants. Depress Anxiety 2008; 25: 1014-1019.
173. Fava GA: Rational use of antidepressant drugs. Psychother Psychosom 2014; 83: 197-204.
174. Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM Jr, Rosenbaum JF, Perlis RH: Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications. J Clin Psychiatry 2007; 68: 52-57.
175. Harvey AT, Silkey BS, Kornstein SG, Clary CM: Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status. J Clin Psychiatry 2007; 68: 951-958.
176. Pozzi M, Radice S, Clementi E, Molteni M, Nobile M: Antidepressants and, suicide and self-injury: causal or casual association? Int J Psychiatry Clin Pract 2016; 20: 47-51.
177. Leon AC, Fiedorowicz JG, Solomon DA, Li C, Coryell WH, Endicott J, Fawcett J, Keller MB: Risk of suicidal behavior with antidepressants in bipolar and unipolar disorders. J Clin Psychiatry 2014; 75: 720-727.
178. Baldessarini RJ, Tondo L, Strombom IM, Dominguez S, Fawcett J, Licinio J, Oquendo MA, Tollefson GD, Valuck RJ, Tohen M: Ecological studies of antidepressant treatment and suicidal risks. Harv Rev Psychiatry 2007; 15: 133-145.
179. Stone MB: The FDA warning on antidepressants and suicidality - why the controversy? N Engl J Med 2014; 371: 1668-1671.
180. Braun C, Bschor T, Franklin J, Baethge C: Suicides and suicide attempts during longterm treatment with antidepressants: a meta- analysis of 29 placebo-controlled studies including 6, 934 patients with major depressive disorder. Psychother Psychosom 2016; 85: 171-179.
181. Teicher MH, Glod C, Cole JO: Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207-210.
182. Henry A, Kisicki MD, Varley C: Efficacy and safety of antidepressant drug treatment in children and adolescents. Mol Psychiatry 2012; 17: 1186-1193.
183. Sharma T, Guski LS, Freund N, Gøtzsche PC: Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ 2016; 352:i65.
184. Miller M, Swanson SA, Azrael D, Pate V, Stürmer T: Antidepressant dose, age, and the risk of deliberate self-harm. JAMA Intern Med 2014; 174: 899-909.
185. Wasserman D, Rihmer Z, Rujescu D, Sarchiapone M, Sokolowski M, Titelman D, Zalsman G, Zemishlany Z, Carli V, Association EP: The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur Psychiatry 2012; 27: 129-141.
186. Turecki G, Brent DA: Suicide and suicidal behaviour. Lancet 2016; 387: 1227-1239.
187. Hawton K, Bergen H, Simkin S, Cooper J, Waters K, Gunnell D, Kapur N: Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 2010; 196: 354-358.
188. White NC, Litovitz T, Clancy C: Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. J Med Toxicol 2008; 4: 238-250.
189. Wilson E, Lader M: A review of the management of antidepressant discontinuation symptoms. Ther Adv Psychopharmacol 2015; 5: 357-368.
190. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015; 84: 72-81.
191. Starcevic V, Brakoulias V, Viswasam K, Berle D: Inconsistent portrayal of medication dependence, withdrawal and discontinuation symptoms in treatment guidelines for anxiety disorders. Psychother Psychosom 2015; 84: 379-380.
192. Chouinard G, Chouinard VA: New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63-71.
193. Narayan V, Haddad PM: Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria. J Psychopharmacol 2011; 25: 306-313.
194. Harvey BH, Slabbert FN: New insights on the antidepressant discontinuation syndrome. Hum Psychopharmacol 2014; 29: 503-516.
195. Belaise C, Gatti A, Chouinard VA, Chouinard G: Persistent post-withdrawal disorders induced by paroxetine, a selective serotonin reuptake inhibitor, and treated with specific cognitive behavioral therapy. Psychother Psychosom 2014; 83: 247-248.
196. Preskorn SH: Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995; 56(suppl 6):12-21.
197. Trindade E, Menon D, Topfer LA, Coloma C: Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998; 159: 1245-1252.
198. Costagliola C, Parmeggiani F, Sebastiani A: SSRIs and intraocular pressure modifications: evidence, therapeutic implications and possible mechanisms. CNS Drugs 2004; 18: 475-484.
199. Ezra DG, Storoni M, Whitefield LA: Simultaneous bilateral acute angle closure glaucoma following venlafaxine treatment. Eye (Lond) 2006; 20: 128-129.
200. Ng B, Sanbrook GM, Malouf AJ, Agarwal SA: Venlafaxine and bilateral acute angle closure glaucoma. Med J Aust 2002; 176: 241.
201. Symes RJ, Etminan M, Mikelberg FS: Risk of angle-closure glaucoma with bupropion and topiramate. JAMA Ophthalmol 2015; 133: 1187-1189.
202. Chen HY, Lin CL, Kao CH: Long-term use of selective serotonin reuptake inhibitors and risk of glaucoma in depression patients. Medicine (Baltimore) 2015; 94:e2041.
203. Chen HY, Lin CL, Lai SW, Kao CH: Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. J Clin Psychiatry 2016, Epub ahead of print.
204. Richa S, Yazbek JC: Ocular adverse effects of common psychotropic agents: a review. CNS Drugs 2010; 24: 501-526.
205. Etminan M, Mikelberg FS, Brophy JM: Selective serotonin reuptake inhibitors and the risk of cataracts: a nested case-control study. Ophthalmology 2010; 117: 1251-1255.
206. Erie JC, Brue SM, Chamberlain AM, Hodge DO: Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. Am J Ophthalmol 2014; 158: 192-197.e191.
207. Rittenhouse PA, Levy AD, Li Q, Bethea CL, Van de Kar LD: Neurons in the hypothalamic paraventricular nucleus mediate the serotonergic stimulation of prolactin secretion via 5-HT1c/2 receptors. Endocrinology 1993; 133: 661-667.
208. Trenque T, Herlem E, Auriche P, Drame M: Serotonin reuptake inhibitors and hyperprolactinaemia: a case/non-case study in the French pharmacovigilance database. Drug Saf 2011; 34: 1161-1166.
209. Ajmal A, Joffe H, Nachtigall LB: Psychotropic- induced hyperprolactinemia: a clinical review. Psychosomatics 2014; 55: 29-36.
210. Mondal S, Saha I, Das S, Ganguly A, Das D, Tripathi SK: A new logical insight and putative mechanism behind fluoxetine-induced amenorrhea, hyperprolactinemia and galactorrhea in a case series. Ther Adv Psychopharmacol 2013; 3: 322-334.
211. Mahasuar R, Majhi P, Ravan JR: Euprolactinemic galactorrhea associated with use of imipramine and escitalopram in a postmenopausal woman. Gen Hosp Psychiatry 2010; 32: 341.e311-e343.
212. Praharaj SK: Euprolactinemic galactorrhea with escitalopram. J Neuropsychiatry Clin Neurosci 2014; 26:E25-E26.
213. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR: Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004; 103: 698-709.
214. Grigoriadis S, VonderPorten EH, Mamisashvili L, Tomlinson G, Dennis C-L, Koren G, Steiner M, Mousmanis P, Cheung A, Radford K, Martinovic J, Ross LE: The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry 2013; 74:e321-e341.
215. Larsen ER, Damkier P, Pedersen LH, Fenger- Gron J, Mikkelsen RL, Nielsen RE, Linde VJ, Knudsen HED, Skaarup L, Videbech P: Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand 2015; 132: 1-28.
216. Reis M, Källén B: Combined use of selective serotonin reuptake inhibitors and sedatives/ hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects: a register study. BMJ Open 2013; 3:e002166.
217. Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE: Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry 2013; 74:e293-e308.
218. Palmsten K, Hernández-Díaz S, Huybrechts KF, Williams PL, Michels KB, Achtyes ED, Mogun H, Setoguchi S: Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ 2013; 347:f4877.
219. Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA; Study NBDP: Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ 2015; 351:h3190.
220. Grigoriadis S, Vonderporten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Ross LE: Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and metaanalysis. BMJ 2014; 348:f6932.
221. Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV: Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebocontrolled clinical trials. Hum Psychopharmacol 2005; 20: 327-341.
222. Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O, Valdimarsdottir UA, Zoega H, Artama M, Gissler M, Malm H, Nørgaard M: Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ 2015; 350:h1798.
223. Bellantuono C, Vargas M, Mandarelli G, Nardi B, Martini MG: The safety of serotonin- noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Hum Psychopharmacol 2015; 30: 143-151.
224. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, Shakir S, Einarson A: Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005; 192: 932-936.
225. Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A, Friedman JM; National Birth Defects Prevention Study: Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010; 203: 52. e1-6.
226. Djulus J, Koren G, Einarson TR, Wilton L, Shakir S, Diav-Citrin O, Kennedy D, Voyer Lavigne S, De Santis M, Einarson A: Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006; 67: 1280-1284.
227. Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, Koren G: A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 2003; 48: 106-110.
228. Ewing G, Tatarchuk Y, Appleby D, Schwartz N, Kim D: Placental transfer of antidepressant medications: implications for postnatal adaptation syndrome. Clin Pharmacokinet 2015; 54: 359-370.
229. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R: Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet (London) 2005; 365: 482-487.
230. Boucher N, Koren G, Beaulac-Baillargeon L: Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations. Ther Drug Monit 2009; 31: 404-409.
231. Eberhard-Gran M, Eskild A, Opjordsmoen S: Use of psychotropic medications in treating mood disorders during lactation: practical recommendations. CNS Drugs 2006; 20: 187-198.
232. Brandes LJ, Arron RJ, Bogdanovic RP, Tong J, Zaborniak CL, Hogg GR, Warrington RC, Fang W, LaBella FS: Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 1992; 52: 3796-3800.
233. Bendele RA, Adams ER, Hoffman WP, Gries CL, Morton DM: Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res 1992; 52: 6931-6935.
234. Gil-Ad I, Zolokov A, Lomnitski L, Taler M, Bar M, Luria D, Ram E, Weizman A: Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancerxenografted mice. Int J Oncol 2008; 33: 277-286.
235. Abdul M, Logothetis CJ, Hoosein NM: Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 1995; 154: 247-250.
236. Cosgrove L, Shi L, Creasey DE, Anaya-Mc- Kivergan M, Myers JA, Huybrechts KF: Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry. PLoS One 2011; 6:e18210.
237. Eom CS, Park SM, Cho KH: Use of antidepressants and the risk of breast cancer: a meta- analysis. Breast Cancer Res Treat 2012; 136: 635-645.
238. Carvalho AF, Hyphantis T, Sales PMG, Soeiro-de-Souza MG, Macédo DS, Cha DS, McIntyre RS, Pavlidis N: Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials. Cancer Treat Rev 2014; 40: 349-355.
239. Ghaemi NS, Vohringer PA, Whitham EA: Antidepressants from a public health perspective: Re-examining effectiveness, suicide, and carcinogenicity. Acta Psychiatr Scand 2013; 127: 89-93.
240. Pae CU: Association between antidepressants and breast/ovarian cancer. Expert Opin Pharmacother 2012; 13: 441-444.
241. Froes Brandao D, Strasser-Weippl K, Goss PE: Prolactin and breast cancer: the need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: a review. Cancer 2016; 122: 184-188.
242. Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, Haffner SM, Price DW, Knowler WC: Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 2008; 31: 420-426.
243. Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH: Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008; 28: 411-417.
244. Fava GA, Tomba E, Tossani E: Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy. Prog Neuropsychopharmacol Biol Psychiatry 2013; 40: 306-311.
245. Fava G, Cosci F, Tomba E: Iatrogenic comorbidity in mental health. Psychother Psychosom 2015; 84(suppl 1):22.
246. Karch FE, Lasagna L: Adverse drug reactions: a critical review. JAMA 1975; 234: 1236-1241.
247. Kaymaz N, van Os J, Loonen AJ, Nolen WA: Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. J Clin Psychiatry 2008; 69: 1423-1436.
248. Guidi J, Tomba E, Fava GA: The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. Am J Psychiatry 2016; 173: 128-137.
249. Fava GA, Guidi J, Rafanelli C, Sonino N: The clinical inadequacy of evidence-based medicine and the need for a conceptual framework based on clinical judgment. Psychother Psychosom 2015; 84: 1-3.